Venous thrombosis (VT) covers a spectrum of venous clotting diseases, primarily deep vein thrombosis and pulmonary embolism. Therapies aim to prevent clot formation under high-risk clinical scenarios (primary prevention), disrupt clot stability (treatment), and/or avert further clots (secondary prevention). Precipitating factors and long-term risk dictate whether treatment will be required for weeks or indefinitely. Over the past decade, standard of care has evolved from heparins and vitamin K antagonists to non-vitamin K antagonist oral anticoagulants (NOACs) inhibiting either thrombin or factor Xa. The next generation of VT therapies targets components of the intrinsic coagulation cascade upstream of the NOACs, and may further reduce bleeding risk. As many treatments in development for other prothrombotic clinical scenarios (e.g., IV catheters or dialysis circuits) also may be applicable to VT, these agents are also included in the VT pipeline.
Medical Conference Coverage
CardioVascular Resource Group (CVrg) is a team of expert analysts who rigorously evaluate the latest new data releases, corporate reports, and news to distill important advances in complex therapeutic areas. Our comprehensive medical congress coverage and continuous market surveillance put these advances into the context of the overall venous thrombosis competitive landscape to help guide strategic and tactical commercial development decisions for our clients.
